

## Stem cell application for osteoarthritis in the knee joint: A minireview

Kristin Uth, Dimitar Trifonov

Kristin Uth, University of Oxford, Old Road Campus Research Building, Old Road Campus, Oxford OX3 7DQ, United Kingdom

Dimitar Trifonov, BioDiscovery, Dundee Science Press, Scotland DD6 8NR, United Kingdom

Author contributions: Uth K and Trifonov D contributed equally to this paper.

Correspondence to: Kristin Uth, MSc, SGC, University of Oxford, Old Road Campus Research Building, Old Road Campus, Roosevelt Drive, Headington, Oxford OX3 7DQ, United Kingdom. [kristin.uth@gmx.de](mailto:kristin.uth@gmx.de)

Telephone: +44-777-6639065

Received: July 27, 2014 Revised: August 31, 2014

Accepted: September 16, 2014

Published online: November 26, 2014

### Abstract

Knee osteoarthritis is a chronic, indolent disease that will affect an ever increasing number of patients, especially the elderly and the obese. It is characterized by degeneration of the cartilage substance inside the knee which leads to pain, stiffness and tenderness. By some estimations in 2030, only in the United States, this medical condition will burden 67 million people. While conventional treatments like physiotherapy or drugs offer temporary relief of clinical symptoms, restoration of normal cartilage function has been difficult to achieve. Moreover, in severe cases of knee osteoarthritis total knee replacement may be required. Total knee replacements come together with high effort and costs and are not always successful. The aim of this review is to outline the latest advances in stem cell therapy for knee osteoarthritis as well as highlight some of the advantages of stem cell therapy over traditional approaches aimed at restoration of cartilage function in the knee. In addition to the latest advances in the field, challenges associated with stem cell therapy regarding knee cartilage regeneration and chondrogenesis *in vitro* and *in vivo* are also outlined and analyzed. Further-

more, based on their critical assessment of the present academic literature the authors of this review share their vision about the future of stem cell applications in the treatment of knee osteoarthritis.

© 2014 Baishideng Publishing Group Inc. All rights reserved.


**Key words:** Multipotent adult mesenchymal stem cells; Osteoarthritis; Knee joint; Clinical trial

**Core tip:** Knee osteoarthritis is a common medical condition in the elderly and the obese. Despite the variety of available conventional treatments for this disease, in recent years stem cell therapy has been applied in an ever increasing number of clinical cases. Therefore the aim of this review is to outline the latest advances in stem cell therapy as a non-pharmacologic treatment for knee osteoarthritis. It also emphasizes on some of the challenges associated with stem cell therapy regarding knee cartilage regeneration and chondrogenesis *in vitro* and *in vivo*.

Uth K, Trifonov D. Stem cell application for osteoarthritis in the knee joint: A minireview. *World J Stem Cells* 2014; 6(5): 629-636 Available from: URL: <http://www.wjgnet.com/1948-0210/full/v6/i5/629.htm> DOI: <http://dx.doi.org/10.4252/wjsc.v6.i5.629>

### INTRODUCTION

Osteoarthritis (OA) of the knee is a chronic, indolent disease that affects all genders, ages and races but is known to be most common in the elderly and in obese people. A degenerative disease of the connective tissue, it mainly affects the articular cartilage (Figure 1)<sup>[1]</sup>. The definition of knee OA varies in reported studies and includes self-reported knee OA (obtained from a questionnaire), radiographic definitions of knee osteoarthritis, and symptom-



**Figure 1** Pathophysiology of knee osteoarthritis. Comparison between a normal and diseased joint (Illustration created after Felson<sup>[3]</sup> and Buja *et al*<sup>[4]</sup>)

atic knee OA (self-reported joint pain and radiographic evidence of OA)<sup>[2]</sup>. Symptoms may include joint pain, stiffness and tenderness. Furthermore, as the cartilage substance decreases, the bone surface may also become affected. This results in development of osteophytes (bone spurs) and direct bone-bone contact. In addition to the stiffness of the joint, the patient tries to avoid pain by minimizing joint movement, which leads to muscle atrophy and laxity of the ligaments<sup>[11-41]</sup>.

The pathogenesis of knee OA have been linked to biomechanical and biochemical changes in the cartilage of the knee joint (*e.g.*, inability to withstand normal mechanical stresses, limited supply of nutrients and oxygen, inadequate synthesis of extracellular matrix components, increased synthesis of tissue-destructive proteinases (matrix metalloproteinases and aggrecanases) and overall apoptosis of chondrocytes)<sup>[4-71]</sup>. Recently, synovial inflammation has also been accredited as a factor limiting knee cartilage repair. Moreover, it correlates to clinical signs of knee OA such as swelling of the knee and inflammatory pain<sup>[7,81]</sup>. It is believed that synovial inflammation is a response of synovial macrophages to cartilage debris and catabolic mediators entering the synovial cavity<sup>[8,91]</sup>.

In regards to the epidemiology of knee OA (Table 1), studies indicate that knee osteoarthritis in men aged 60 to 64 is usually found in the right knee (23%) than in the left knee (16.3%), while distribution seems to be more evenly balanced in women of the same age (right knee, 24.2%; left knee, 24.7%)<sup>[6,101]</sup>. A variety of endogenous (*e.g.*, age, sex) and exogenous (obesity, patient's lifestyle) risk factors for OA have also been outlined<sup>[2,6,11-141]</sup>. Recently, a number of genome wide association studies (GWAS) (*e.g.*, Rotter-

dam GWAS<sup>[151]</sup>, Tokyo GWAS<sup>[151]</sup>, Chingford Study<sup>[161]</sup>) have highlighted the significance of gene mutations (*e.g.*, in *GDF5*) for the development of knee OA<sup>[15-211]</sup>. Additionally, cross-sectional studies indicate that the risk of knee OA is 1.9 to 13.0 times higher among underground coal miners when compared to a control population; presumably, due to frequent work in the kneeling or squatting position<sup>[61]</sup>. Construction workers, especially floorers, also have a significantly elevated prevalence of knee OA<sup>[61]</sup>.

As of clinical diagnosis of knee OA, it is complex as during the physical examination of the patient it is needed to confirm and characterise joint involvement, as well as to exclude pain and functional syndromes linked to other causes (*e.g.*, inflammatory arthritis or damaged meniscus)<sup>[3,11,221]</sup>. In addition to non-surgical treatments for this condition such as physiotherapy, diet rich in vitamin D and supportive sport (*e.g.*, swimming)<sup>[10,23,241]</sup>, there are several medicinal and homeopathic products on the market, which promise pain relief and a decrease in symptoms. However, researchers are keen to investigate new treatments to combat OA of the knee.

## STEM CELL TREATMENT

Self-regeneration of the cartilage, which includes chondrocytes, ground substance (cartilage matrix) and elastin fibers, is a slow process which results in new cartilage substance that is not stable for intensive burdens. The fluid inside the joint contains mesenchymal stem cells (MSCs) which can differentiate into chondrocytes, but new deposited cartilage is very fragile and can be destroyed by applying a minimal amount of stress on the

**Table 1 Worldwide prevalence (2005) of knee osteoarthritis**

	Knee OA prevalence
Europe	
Western	0.1689
Central	0.1889
Eastern	0.1914
Asia	
Middle East	0.1764
South	0.1563
East	0.1683
Southeast	0.1704
Central	0.1854
Pacific	0.1704
Africa	
North	0.1764
West Sub-Saharan	0.1574
East Sub-Saharan	0.1544
Central Sub-Saharan	0.1528
South	0.1822
Australia and Oceania	
Australia	0.1736
Oceania	0.1813
North America	
United States and Canada	0.1792
Central America	0.1777
Caribbean	0.1756
South America	
Andean	0.1751
Tropical	0.1691
Southern	0.1693

Combined value for male and female, aged 30-100 (Data adapted from March *et al*<sup>[10]</sup>). OA: Osteoarthritis.

joint. Additionally there is only a limited quantity of MSCs in the joint available to differentiate and the process of differentiation is slow<sup>[1,25]</sup>.

## STEM CELL MANAGEMENT

The aim in using stem cells is to support the self-healing process of the knee joint cartilage which results in relief from OA symptoms<sup>[26-32]</sup>. This treatment should be used in conjunction with additional treatment in order to improve patients' functional status and quality of life. However, osteoarthritis cannot be cured by any radical treatment at the moment.

The stem cell candidates for use in these therapies are multipotent adult MSCs, because they are available in several tissues, including in the fluid inside the joint, and have the ability to differentiate into cells of the chondrogenic lineage<sup>[33,34]</sup>. Pittenger *et al*<sup>[35]</sup> have described that MSCs could be cultured without losing their multilineage differentiation potential and it has been shown that MSCs are capable of undergoing chondrogenic differentiation both *in-vitro* and *in-vivo*. MSCs can be harvested from bone marrow, periosteum, trabecular bone, adipose tissue, synovium, skeletal muscle and deciduous teeth<sup>[36]</sup>. Regardless of their origin they have the capacity to differentiate into many cell types, including cells of connective tissue lineages, including bone, fat, cartilage and muscle<sup>[26,37]</sup>. MSCs were first identified in the pioneering

studies of Friedenstein and Petrakova (1966)<sup>[33]</sup> and are of major interest of research in the treatment of arthritis, in particular OA.

Multipotent adult mesenchymal stem cells are extensively investigated - in particular their behaviour in cell culture: how do they stay multipotent after several passages; how is chondrogenesis triggered in MSCs<sup>[32]</sup>. There are no definitive markers identified for MSCs yet, but the immunophenotype is positive for the proteins and enzymes STRO-1, CD73, CD146, CD105, CD106, CD166 and negative for CD11b, CD45, CD34, CD31 and CD117. These are the most reliable for characterizing MSCs<sup>[34,36]</sup>.

There are several other criteria which must be considered when growing MSCs in culture. One of the most crucial criteria is the availability of characterized factors which stimulate the anabolic activity in cartilage including transforming growth factor (TGF)- $\beta$ , bone morphogenetic protein (BMP), fibroblast growth factors (FGF), insulin growth factor (IGF)-1, hedgehog (hh) and Wntless (Wnt) proteins<sup>[26]</sup>. These factors are signalling proteins that belong to the tyrosine kinase family of proteins (transmembrane proteins) that activate several downstream processes leading to cell proliferation, survival, growth and a reduction in apoptotic signalling.

Growth factors like FGF2 or transforming growth factor beta induce a positive differentiation of MSCs<sup>[38]</sup>. Moreover, the development of methods was required to develop the cartilage phenotype without hypertrophy, fibrogenesis or ossification. In addition, a delivery system was devised to target cells in a lesion, but without inhibiting their chondrogenic differentiation or the integrity of repaired tissue<sup>[39]</sup>.

## CLINICAL TRIALS

In recent years several clinical protocols for MSCs have been tested<sup>[26-32,40]</sup>. In general, MSC related therapeutic approaches have a significant advantage to traditional surgical approaches such as autologous chondrocyte transplantation: no cartilage biopsy is necessary, thus no external stress and cellular damage are applied at the donor-site articular surface<sup>[31]</sup>. Moreover, direct intra-articular injection of MSC is perceived as a technically simple way to treat advanced OA of the knee<sup>[32]</sup>.

### Stem cells from patients

MSCs and platelet-rich plasma are harvested from the patient to be treated thus ensuring that the patient's immune system will not reject the cells<sup>[41]</sup>. These cells are already specific for the patient's body but they have to be processed before intra-articular injection in the knee joint. This process includes separation of the MSCs by centrifugation and other purification steps. With the aim in mind of increasing cartilage build-up, chondrogenic activity of the harvested cells has to be evaluated, as well as glycosaminoglycan and type II collagen deposition, before reinjection<sup>[29]</sup>. The MSCs are tested *in vitro* for their

ability to undergo chondrogenic differentiation under the previous described conditions. Glycosaminoglycan and type II collagen are components of the matrix of cartilage which induces and supports the differentiation of MSCs into chondrocytes. During this procedure it is important that the joint is stressed as little as possible because the newly differentiated cartilage is highly susceptible to damage.

In regards to recent advancements in the field, Neporent<sup>[42]</sup> mentioned several pro and contra factors for stem cell injection in the knee joint. MSCs treatment offers the significant advantage of a quick and relatively uneventful recovery. Furthermore the majority of patients became ambulatory within 24 h. There are no reasonable arguments against treatment with the patient's stem cells, but there are several issues that have to be considered that are likely to make it financially less attractive. Firstly, at approximately \$4000 per knee for stem cell reinjection, which will not be covered by health insurance, this treatment is not for affordable by everyone. Secondly, there are several criteria for eligibility for treatment of osteoarthritis with stem cells preparations. For one thing, the body-mass-index (BMI) should not be more than 35. Obesity, as previously mentioned, is a high risk factor for OA, because of the high stress which results on the knee joint. Stem cell treatment is reasonable, if it can be ensured that there would be no high stress on the joint. Furthermore this treatment is applicable only if the degeneration of the cartilage is not complete. As long as cartilage and joint fluid is available, stem cells can differentiate, because of necessary factors are present in the fluid and matrix but in severe cases, with bone-bone contact, stem cell treatment is unlikely to work. Most important for the patient is to minimize physical activity in the immediate period after the therapy because the stress to the joint reduces the chance of successful recovery. Furthermore it is likely that more than one treatment session would be required, meaning a greater investment of time and money.

In addition to the intra-articular injection of MSCs, Nöth *et al.*<sup>[32]</sup> also highlighted the use of MSCs as progenitor cells to engineer cartilage implants that can be used to repair chondral and osteochondral lesions, or as trophic producers of bioactive factors to initiate endogenous regenerative activities in the OA joint.

### **Stem cells from donors**

Another potential source of stem cells, which can be used in therapies, is allogeneic MSCs. They are harvested from donated human umbilical cord tissue (HUCT) after normal, healthy births where the mother has been tested for infectious diseases and has a screened medical history. These harvested MSCs are then screened to International Blood Bank Standards (Stem Cell Institute, 2012).

Umbilical cord tissue provides an abundant supply of mesenchymal stem cells avoiding the requirement to harvest stem cells by invasive procedures such as liposuction or bone marrow aspiration. There is evidence show-

ing that mesenchymal stem cells from umbilical cords are more robust than those from other sources such as fat<sup>[43]</sup>.

Rush University Medical Center<sup>[44]</sup>, 2013, described the preparation of MSCs harvested from donated umbilical cord tissue: The cells are mixed with hyaluronan, a natural polymer that plays an important role in wound healing and deposition of cartilage, and are subsequently re-injected into the knee joint. In addition they also described a two-year Phase I/ II a clinical study in which a total of 12 participants aged 18 years and older, with a body mass index of less than 35 were enrolled. Initially, six individuals with lesions sized 2 to 5 cm were recruited into the study and an additional six volunteers with lesions larger than 5 cm were enrolled subsequently. Each participant went through an eligibility screening followed by a 12-mo observation period to determine the safety and efficacy of the therapy with an additional long-term follow-up evaluation at 24 mo.

Basically both treatment protocols, both for the MSCs from the patient and from a donor, were identical. Any differences in the MSCs and in some characteristics of the cells arose due to those from the patient themselves, from fat or bone marrow, being "older" than MSCs from umbilical cord and may therefore lack potential for proliferation and/or differentiation.

---

## **CONCLUSION**

---

In recent years the role of stem cells in health and disease is a topic of high interest for biomedical research, especially regenerative medicine<sup>[33,45,46]</sup>, including non-pharmacologic treatment of knee OA<sup>[25,40,47]</sup>, and drug discovery<sup>[48-50]</sup>. At the moment there is an increase in the number of clinical cases utilizing stem cell therapy for knee OA, however, many clinical protocols are still under development<sup>[26,30,40]</sup>.

### **Future perspectives about clinical trials with stem cells from patients**

Based on the current status of clinical investigations regarding autologous stem cell therapy for OA of the knee some authors have expressed concerns about the issues of dosing, timing of intervention, type of MSCs, mode and route of delivery of MSCs in clinical studies<sup>[51-56]</sup>. Therefore the need for a gold standard for autologous stem cell therapy for knee OA arises, which (hopefully) will be the aim of future clinical trials. Another interesting trend is the increased research interest in scaffold assisted or scaffoldless grafts of MSCs as a method to restore the structural and biomechanical characteristics of the OA affected knee<sup>[57-62]</sup>. MSC grafts may even prove to be a viable alternative to total knee replacement in the near future. However, we still have to wait for a 100% effective and also low cost clinical procedure to be developed.

### **Future perspectives about clinical trials with stem cells from donors**

The use of human umbilical cord-derived mesenchymal



stem cells (hUC-MSCs) in clinical trials for treatment of knee OA faces the same challenges as clinical trials with other types of MSC in terms of stem cell handling<sup>[43]</sup>. There is also the need for more relevant clinical data, so it would be beneficial to have more clinical trials for knee OA, which utilize hUC-MSCs.

### **Future perspectives about basic research in knee cartilage regeneration and chondrogenesis *in vitro* and *in vivo***

Nowadays basic research in chondrogenesis *in vitro* and *in vivo* is primarily focus on increasing the efficacy of stem cells in terms of tissue repair<sup>[57-62]</sup>. However, the issues of stem cell characterization and tumorigenesis *in vivo* are somewhat overlooked.

Until relatively recently, the genomic profile of the stem cell lines maintained *in vitro* was only assessed in terms of ploidy and karyotype, as it was known that cultured cells may exhibit loss or gain of chromosome fragments or whole chromosomes and/or genomic rearrangements<sup>[63-65]</sup>. After the introduction of the concept for individual capacity for DNA repair and for maintenance of genomic integrity in research and diagnostic practice, its applicability as a complex marker for the proliferative potential and/or the differentiation capacity of undifferentiated cells has been extensively discussed<sup>[66-69]</sup>. Some authors have advised that the minimal panel for characterisation of *in vitro* maintained pluripotent cell lines ought to include markers for individual capacity for repair of genotoxic damage and maintenance of genomic integrity<sup>[69-71]</sup>. Some stem cells types (mesenchymal stem cells, haematopoietic cells from bone marrow and iPSC) have been shown to lose *TP53* gene copies during *in vitro* culturing (detected as loss of heterozygosity for markers at the *TP53* locus)<sup>[72]</sup>. Shetzer *et al*<sup>[72]</sup> also reported that the cells with loss of heterozygosity were more often than not identified as the origin of the teratoma-like tumours developing after the cells were transplanted in mice.

All those findings in basic stem cell biology will likely influence the development of more advanced (in terms of cell characterization) stem cell culturing and differentiation protocols and lead to the development of a gold standard in clinical trials with MSCs.

### **Conclusion**

In conclusion, stem cell therapy may not become a standard treatment for knee OA till the end of the decade due to various aspects regarding the clinical safety (*e.g.*, risk of complications after surgery, compatibility of donor stem cells) and the affordability of this treatment for the general public. Moreover, there is still no sufficient amount of clinical data on the effectiveness of stem cell therapy when compared with pharmacological treatments for this particular disease<sup>[47]</sup>. There is also the emerging application of nutraceuticals as a possible alternative to drugs for knee osteoarthritis<sup>[73,74]</sup>. So here comes the question: what will future clinical trials for knee OA and OA in general evaluate: novel pharmaceuticals, novel nu-

traceuticals, improved stem cell therapies?

## **REFERENCES**

- 1 **Gupta PK**, Das AK, Chullikana A, Majumdar AS. Mesenchymal stem cells for cartilage repair in osteoarthritis. *Stem Cell Res Ther* 2012; **3**: 25 [PMID: 22776206 DOI: 10.1186/scrt116]
- 2 **Chaganti RK**, Lane NE. Risk factors for incident osteoarthritis of the hip and knee. *Curr Rev Musculoskelet Med* 2011; **4**: 99-104 [PMID: 21808997 DOI: 10.1007/s12178-011-9088-5]
- 3 **Felson DT**. Clinical practice. Osteoarthritis of the knee. *N Engl J Med* 2006; **354**: 841-848 [PMID: 16495396 DOI: 10.1056/NEJMc051726]
- 4 **Buja LM**, Krüger GRF. *Netter's Illustrated Human Pathology*. 2nd ed. Suite, PA: Elsevier Inc., 2014: 390
- 5 **Bijlsma JW**, Berenbaum F, Lafeber FP. Osteoarthritis: an update with relevance for clinical practice. *Lancet* 2011; **377**: 2115-2126 [PMID: 21684382 DOI: 10.1016/S0140-6736(11)60243-2]
- 6 **Michael JW**, Schlüter-Brust KU, Eysel P. The epidemiology, etiology, diagnosis, and treatment of osteoarthritis of the knee. *Dtsch Arztebl Int* 2010; **107**: 152-162 [PMID: 20305774 DOI: 10.3238/arztebl.2010.0152]
- 7 **Lories RJ**, Luyten FP. The bone-cartilage unit in osteoarthritis. *Nat Rev Rheumatol* 2011; **7**: 43-49 [PMID: 21135881 DOI: 10.1038/nrrheum.2010.197]
- 8 **Sellam J**, Berenbaum F. The role of synovitis in pathophysiology and clinical symptoms of osteoarthritis. *Nat Rev Rheumatol* 2010; **6**: 625-635 [PMID: 20924410 DOI: 10.1038/nrrheum.2010.159]
- 9 **Heinegård D**, Saxne T. The role of the cartilage matrix in osteoarthritis. *Nat Rev Rheumatol* 2011; **7**: 50-56 [PMID: 21119607 DOI: 10.1038/nrrheum.2010.198]
- 10 **March L**, Hoy D, Smith E, Blyth F, Cross M, Fransen M, Sanchez Riera L, Vos T, Buchbinder R, Brooks P, Woolf A. Global Burden of Disease (GBD) 2010. Bone & Joint Decade 2010-2020 Global Alliance for Musculoskeletal Health World Network Conference 2012, cited 2014-07-20. Available from: URL: [http://bjdonline.org/wp-content/uploads/2013/03/L-March\\_BJD-GLOBAL-NETWORK\\_Global-Burden-MSK-1990-20101.pdf](http://bjdonline.org/wp-content/uploads/2013/03/L-March_BJD-GLOBAL-NETWORK_Global-Burden-MSK-1990-20101.pdf)
- 11 **Pelletier JM**, Pelletier JP, editors. *Understanding Osteoarthritis from Bench to Bedside*. Kerala, India: Research Signpost, 2011: 1-26
- 12 **Murray CJ**, Vos T, Lozano R, Naghavi M, Flaxman AD, Michaud C, Ezzati M, Shibuya K, Salomon JA, Abdalla S, Aboyans V, Abraham J, Ackerman J, Aggarwal R, Ahn SY, Ali MK, Alvarado M, Anderson HR, Anderson LM, Andrews KG, Atkinson C, Baddour LM, Bahalim AN, Barker-Collo S, Barrero LH, Bartels DH, Basáñez MG, Baxter A, Bell ML, Benjamin EJ, Bennett D, Bernabé E, Bhalla K, Bhandari B, Bikbov B, Bin Abdulhak A, Birbeck G, Black JA, Blencowe H, Blore JD, Blyth F, Bolliger I, Bonaventure A, Boufous S, Bourne R, Boussinesq M, Braithwaite T, Brayne C, Bridgett L, Brooker S, Brooks P, Brugha TS, Bryan-Hancock C, Bucello C, Buchbinder R, Buckle G, Budke CM, Burch M, Burney P, Burstein R, Calabria B, Campbell B, Canter CE, Carabin H, Carapetis J, Carmona L, Cella C, Charlson F, Chen H, Cheng AT, Chou D, Chugh SS, Coffeng LE, Colan SD, Colquhoun S, Colson KE, Condon J, Connor MD, Cooper LT, Corriere M, Cortinovis M, de Vaccaro KC, Couser W, Cowie BC, Criqui MH, Cross M, Dabhadkar KC, Dahiya M, Dahodwala N, Damsere-Derry J, Danaei G, Davis A, De Leo D, Degenhardt L, Dellavalle R, Delossantos A, Denenberg J, Derrett S, Des Jarlais DC, Dharmaratne SD, Dherani M, Diaz-Torne C, Dolk H, Dorsey ER, Driscoll T, Duber H, Ebel B, Edmond K, Elbaz A, Ali SE, Erskine H, Erwin PJ, Espindola P, Ewoigbokhan SE, Farzadfar F, Feigin V, Felson DT, Ferrari A, Ferri CP, Fèvre EM, Finucane MM, Flaxman S, Flood L, Foreman

- K, Forouzanfar MH, Fowkes FG, Fransen M, Freeman MK, Gabbe BJ, Gabriel SE, Gakidou E, Ganatra HA, Garcia B, Gaspari F, Gillum RF, Gmel G, Gonzalez-Medina D, Gosse- lin R, Grainger R, Grant B, Groeger J, Guillemin F, Gunnell D, Gupta R, Haagsma J, Hagan H, Halasa YA, Hall W, Haring D, Haro JM, Harrison JE, Havmoeller R, Hay RJ, Higashi H, Hill C, Hoen B, Hoffman H, Hotez PJ, Hoy D, Huang JJ, Ibeanusi SE, Jacobsen KH, James SL, Jarvis D, Jasrasaria R, Jayaraman S, Johns N, Jonas JB, Karthikeyan G, Kassebaum N, Kawakami N, Keren A, Khoo JP, King CH, Knowlton LM, Kobusingye O, Koranteng A, Krishnamurthi R, Laden F, Lalloo R, Laslett LL, Lathlean T, Leasher JL, Lee YY, Leigh J, Levinson D, Lim SS, Limb E, Lin JK, Lipnick M, Lipshultz SE, Liu W, Loane M, Ohno SL, Lyons R, Mabweijano J, MacIntyre MF, Malekzadeh R, Mallinger L, Manivannan S, Marcenes W, March L, Margolis DJ, Marks GB, Marks R, Matsumori A, Matzopoulos R, Mayosi BM, McAnulty JH, McDermott MM, McGill N, McGrath J, Medina-Mora ME, Meltzer M, Mensah GA, Merriman TR, Meyer AC, Miglioli V, Miller M, Miller TR, Mitchell PB, Mock C, Mocumbi AO, Moffitt TE, Mokdad AA, Monasta L, Montico M, Moradi- Lakeh M, Moran A, Morawska L, Mori R, Murdoch ME, Mwaniki MK, Naidoo K, Nair MN, Naldi L, Narayan KM, Nelson PK, Nelson RG, Nevitt MC, Newton CR, Nolte S, Norman P, Norman R, O'Donnell M, O'Hanlon S, Olives C, Omer SB, Ortblad K, Osborne R, Ozgediz D, Page A, Pahari B, Pandian JD, Rivero AP, Patten SB, Pearce N, Padilla RP, Perez-Ruiz F, Perico N, Pesudovs K, Phillips D, Phillips MR, Pierce K, Pion S, Polanczyk GV, Polinder S, Pope CA, Popova S, Porrini E, Pourmalek F, Prince M, Pullan RL, Ramaiah KD, Ranganathan D, Razavi H, Regan M, Rehm JT, Rein DB, Remuzzi G, Richardson K, Rivara FP, Roberts T, Robinson C, De León FR, Ronfani L, Room R, Rosenfeld LC, Rushton L, Sacco RL, Saha S, Sampson U, Sanchez-Riera L, San- man E, Schwebel DC, Scott JG, Segui-Gomez M, Shahraz S, Shepard DS, Shin H, Shivakoti R, Singh D, Singh GM, Singh JA, Singleton J, Sleet DA, Sliwa K, Smith E, Smith JL, Stapel- berg NJ, Steer A, Steiner T, Stolk WA, Stovner LJ, Sudfeld C, Syed S, Tamburlini G, Tavakkoli M, Taylor HR, Taylor JA, Taylor WJ, Thomas B, Thomson WM, Thurston GD, Tleyjeh IM, Tonelli M, Towbin JA, Truelsen T, Tsilimbaris MK, Ubeda C, Undurraga EA, van der Werf MJ, van Os J, Vavilala MS, Venketasubramanian N, Wang M, Wang W, Watt K, Weatherall DJ, Weinstock MA, Weintraub R, Weiss- kopf MG, Weissman MM, White RA, Whiteford H, Wiebe N, Wiersma ST, Wilkinson JD, Williams HC, Williams SR, Witt E, Wolfe F, Woolf AD, Wulf S, Yeh PH, Zaidi AK, Zheng ZJ, Zonies D, Lopez AD, AlMazroa MA, Memish ZA. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. *Lancet* 2012; **380**: 2197-2223 [PMID: 23245608 DOI: 10.1016/S0140-6736(12)61689-4]
- 13 **Palazzo C**, Ravaud JF, Papelard A, Ravaud P, Poiraudreau S. The burden of musculoskeletal conditions. *PLoS One* 2014; **9**: e90633 [PMID: 24595187 DOI: 10.1371/journal.pone.0090633]
- 14 **Wong R**, Davis AM, Badley E, Grewal R, Mohammed M. Prevalence of Arthritis and Rheumatic Diseases around the World. A Growing Burden and Implications for Health Care Needs (April 2010). Arthritis Community Research and Evaluation Unit, 2010. Cited 2014-07-22. Available from: URL: <http://www.modelsofcare.ca/pdf/10-02.pdf>
- 15 **Loughlin J**. Osteoarthritis year 2010 in review: genetics. *Osteoarthritis Cartilage* 2011; **19**: 342-345 [PMID: 21320617 DOI: 10.1016/j.joca.2011.01.020]
- 16 **Aref-Eshghi E**, Zhang Y, Hart D, Valdes AM, Furey A, Martin G, Sun G, Rahman P, Arden N, Spector TD, Zhai G. SMAD3 is associated with the total burden of radiographic osteoarthritis: the Chingford study. *PLoS One* 2014; **9**: e97786 [PMID: 24852296 DOI: 10.1371/journal.pone.0097786]
- 17 **Wu X**, Kondragunta V, Kornman KS, Wang HY, Duff GW, Renner JB, Jordan JM. IL-1 receptor antagonist gene as a predictive biomarker of progression of knee osteoarthritis in a population cohort. *Osteoarthritis Cartilage* 2013; **21**: 930-938 [PMID: 23602982 DOI: 10.1016/j.joca.2013.04.003]
- 18 **Valdes AM**, Spector TD. The genetic epidemiology of osteoarthritis. *Curr Opin Rheumatol* 2010; **22**: 139-143 [PMID: 20090528 DOI: 10.1097/BOR.0b013e3283367a6e]
- 19 **Hochberg MC**, Yerges-Armstrong L, Mitchell BD. Osteoarthritis susceptibility genes continue trickling in. *Lancet* 2012; **380**: 785-787 [PMID: 22763109 DOI: 10.1016/S0140-6736(12)60818-6]
- 20 **Valdes AM**, Spector TD. Genetic epidemiology of hip and knee osteoarthritis. *Nat Rev Rheumatol* 2011; **7**: 23-32 [PMID: 21079645 DOI: 10.1038/nrrheum.2010.191]
- 21 **Sandell LJ**. Etiology of osteoarthritis: genetics and synovial joint development. *Nat Rev Rheumatol* 2012; **8**: 77-89 [PMID: 22231237 DOI: 10.1038/nrrheum.2011.199]
- 22 **Paradowski PT**. Osteoarthritis of the Knee: Assessing the Disease. *Editorial Health Care: Current Reviews* 2014; **2**: e103 [DOI: 10.4172/hccr.1000e103]
- 23 **Riecke BF**, Christensen R, Christensen P, Leeds AR, Boesen M, Lohmander LS, Astrup A, Bliddal H. Comparing two low-energy diets for the treatment of knee osteoarthritis symptoms in obese patients: a pragmatic randomized clinical trial. *Osteoarthritis Cartilage* 2010; **18**: 746-754 [PMID: 20206314 DOI: 10.1016/j.joca.2010.02.012]
- 24 **Messier SP**, Mihalko SL, Legault C, Miller GD, Nicklas BJ, DeVita P, Beavers DP, Hunter DJ, Lyles MF, Eckstein F, Williamson JD, Carr JJ, Guermazi A, Loeser RF. Effects of intensive diet and exercise on knee joint loads, inflammation, and clinical outcomes among overweight and obese adults with knee osteoarthritis: the IDEA randomized clinical trial. *JAMA* 2013; **310**: 1263-1273 [PMID: 24065013 DOI: 10.1001/jama.2013.277669]
- 25 **Kon E**, Filardo G, Roffi A, Andriolo L, Marcacci M. New trends for knee cartilage regeneration: from cell-free scaffolds to mesenchymal stem cells. *Curr Rev Musculoskelet Med* 2012; **5**: 236-243 [PMID: 22797862 DOI: 10.1007/s12178-012-9135-x]
- 26 **Barry FP**, Murphy JM. Mesenchymal stem cells: clinical applications and biological characterization. *Int J Biochem Cell Biol* 2004; **36**: 568-584 [PMID: 15010324 DOI: 10.1016/j.biocel.2003.11.001]
- 27 **Davatchi F**, Abdollahi BS, Mohyeddin M, Shahram F, Nikbin B. Mesenchymal stem cell therapy for knee osteoarthritis. Preliminary report of four patients. *Int J Rheum Dis* 2011; **14**: 211-215 [PMID: 21518322 DOI: 10.1111/j.1756-185X.2011.01599.x]
- 28 **Vinartier C**, Bouffi C, Merceron C, Gordeladze J, Brondello JM, Jorgensen C, Weiss P, Guicheux J, Noël D. Cartilage tissue engineering: towards a biomaterial-assisted mesenchymal stem cell therapy. *Curr Stem Cell Res Ther* 2009; **4**: 318-329 [PMID: 19804369]
- 29 **Murphy JM**, Dixon K, Beck S, Fabian D, Feldman A, Barry F. Reduced chondrogenic and adipogenic activity of mesenchymal stem cells from patients with advanced osteoarthritis. *Arthritis Rheum* 2002; **46**: 704-713 [PMID: 11920406 DOI: 10.1002/art.10118]
- 30 **Koelling S**, Miosge N. Stem cell therapy for cartilage regeneration in osteoarthritis. *Expert Opin Biol Ther* 2009; **9**: 1399-1405 [PMID: 19793003 DOI: 10.1517/14712590903246370]
- 31 **Mobasheri A**, Csaki C, Clutterbuck AL, Rahmanzadeh M, Shakibaei M. Mesenchymal stem cells in connective tissue engineering and regenerative medicine: applications in cartilage repair and osteoarthritis therapy. *Histol Histopathol* 2009; **24**: 347-366 [PMID: 19130405]
- 32 **Nöth U**, Steinert AF, Tuan RS. Technology insight: adult mesenchymal stem cells for osteoarthritis therapy. *Nat Clin Pract Rheumatol* 2008; **4**: 371-380 [PMID: 18477997 DOI: 10.1038/ncprheum0816]

- 33 **Chamberlain G**, Fox J, Ashton B, Middleton J. Concise review: mesenchymal stem cells: their phenotype, differentiation capacity, immunological features, and potential for homing. *Stem Cells* 2007; **25**: 2739-2749 [PMID: 17656645 DOI: 10.1634/stemcells.2007-0197]
- 34 **Kolf CM**, Cho E, Tuan RS. Mesenchymal stromal cells. Biology of adult mesenchymal stem cells: regulation of niche, self-renewal and differentiation. *Arthritis Res Ther* 2007; **9**: 204 [PMID: 17316462 DOI: 10.1186/ar2116]
- 35 **Pittenger MF**, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, Moorman MA, Simonetti DW, Craig S, Marshak DR. Multilineage potential of adult human mesenchymal stem cells. *Science* 1999; **284**: 143-147 [PMID: 10102814 DOI: 10.1126/science.284.5411.143]
- 36 **Chen FH**, Rousche KT, Tuan RS. Technology Insight: adult stem cells in cartilage regeneration and tissue engineering. *Nat Clin Pract Rheumatol* 2006; **2**: 373-382 [PMID: 16932723 DOI: 10.1038/ncprheum0216]
- 37 **Baghaban Eslaminejad M**, Malakooty Poor E. Mesenchymal stem cells as a potent cell source for articular cartilage regeneration. *World J Stem Cells* 2014; **6**: 344-354 [PMID: 25126383 DOI: 10.4252/wjsc.v6.i3.344]
- 38 **Im GI**, Jung NH, Tae SK. Chondrogenic differentiation of mesenchymal stem cells isolated from patients in late adulthood: the optimal conditions of growth factors. *Tissue Eng* 2006; **12**: 527-536 [PMID: 16579686 DOI: 10.1089/ten.2006.12.527]
- 39 **Steinert AF**, Ghivizzani SC, Rethwilm A, Tuan RS, Evans CH, Nöth U. Major biological obstacles for persistent cell-based regeneration of articular cartilage. *Arthritis Res Ther* 2007; **9**: 213 [PMID: 17561986 DOI: 10.1186/ar2195]
- 40 **Diekman BO**, Guilak F. Stem cell-based therapies for osteoarthritis: challenges and opportunities. *Curr Opin Rheumatol* 2013; **25**: 119-126 [PMID: 23190869 DOI: 10.1097/BOR.0b013e32835aa28d]
- 41 **Wolfstadt JL**, Cole BJ, Ogilvie-Harris DJ, Viswanathan S, Chahal J. Current Concepts: The Role of Mesenchymal Stem Cells in the Management of Knee Osteoarthritis. *Sports Health: A Multidisciplinary Approach*, 2014 [DOI: 10.1177/1941738114529727]
- 42 **Neporent L**. Stem Cells: Alternative to Knee Replacement? Cited 2014-07-23. Available from: URL: <http://stemcellarts.com/stem-cells-alternative-to-knee-replacement/>
- 43 **Fan CG**, Zhang QJ, Zhou JR. Therapeutic potentials of mesenchymal stem cells derived from human umbilical cord. *Stem Cell Rev* 2011; **7**: 195-207 [PMID: 20676943 DOI: 10.1007/s12015-010-9168-8]
- 44 Stem cell therapy to repair damaged knee cartilage. Rush University Medical Center. Cited: 2014-01-24. Available from : URL: <http://www.sciencedaily.com/releases/2013/01/130124163246.htm>
- 45 **Krampera M**, Pizzolo G, Aprili G, Franchini M. Mesenchymal stem cells for bone, cartilage, tendon and skeletal muscle repair. *Bone* 2006; **39**: 678-683 [PMID: 16765663 DOI: 10.1016/j.bone.2006.04.020]
- 46 **Wu SM**, Hochedlinger K. Harnessing the potential of induced pluripotent stem cells for regenerative medicine. *Nat Cell Biol* 2011; **13**: 497-505 [PMID: 21540845 DOI: 10.1038/ncb0511-497]
- 47 **Singh JA**. Stem cells and other innovative intra-articular therapies for osteoarthritis: what does the future hold? *BMC Med* 2012; **10**: 44 [PMID: 22551396 DOI: 10.1186/1741-7015-10-44]
- 48 **Zhelev N**, Trifonov D, Wang S, El Serafi I, Mitev V. From Roscovitine to CYC 202 to Seliciclib – from bench to bedside: discovery and development. *BioDiscovery* 2013; **10**: 1 [DOI: 10.7750/BioDiscovery.2013.10.1]
- 49 **Zhelev N**, Tummala H, Trifonov D., D' Ascanio I., Oluwaseun O.A., Fischer P.M. Recent advances in the development of cyclin-dependent kinase inhibitors as new therapeutics in oncology and cardiology *Curr Opin Biotech* 2013; **24**: 25 [DOI: 10.1016/j.copbio.2013.05.036]
- 50 **Trifonov D**, Tummala H., Clements S., Zhelev N. Effect of roscovitine on cardiac hypertrophy in human stem cell derived cardiomyocytes. *Curr Opin Biotech* 2013; **24**: 114 [DOI: 10.1016/j.copbio.2013.05.354]
- 51 **Viswanathan S**, Gómez-Aristizábal A. Review of Patents and Commercial Opportunities Involving Mesenchymal Stromal Cells (MSCs) Therapies in Osteoarthritis. *Recent Patents on Regenerative Medicine* 2014; **4**: 1-15 [DOI: 10.2174/2210296504666140307010938]
- 52 **Wei CC**, Lin AB, Hung SC. Mesenchymal stem cells in regenerative medicine for musculoskeletal diseases: bench, bedside, and industry. *Cell Transplant* 2014; **23**: 505-512 [PMID: 24816447 DOI: 10.3727/096368914X678328]
- 53 **Jorgensen C**, Noël D. Mesenchymal stem cells in osteo-articular diseases: an update. Cited 2014-07-26. Available from: URL: [http://www.ijmcm.org/files/site1/user\\_files\\_a195ea/eng/jorgensen-A-10-37-1-8b83de9.pdf](http://www.ijmcm.org/files/site1/user_files_a195ea/eng/jorgensen-A-10-37-1-8b83de9.pdf)
- 54 **Guérit D**, Maumus M, Apparailly F, Jorgensen C, Noël D. Therapeutic mesenchymal stem or stromal cells in rheumatic diseases: rationale, clinical data and perspectives. *J Clin Invest* 2011; **121**: 1269-1277 [DOI: 10.1172/JCI411102]
- 55 **Wang W**, Cao W. Treatment of osteoarthritis with mesenchymal stem cells. *Sci China Life Sci* 2014; **57**: 586-595 [PMID: 24849513 DOI: 10.1007/s11427-014-4673-7]
- 56 **Montoya F**, Martínez F, García-Robles M, Balmaceda-Aguilera C, Koch X, Rodríguez F, Silva-Álvarez C, Salazar K, Ulloa V, Nualart F. Clinical and experimental approaches to knee cartilage lesion repair and mesenchymal stem cell chondrocyte differentiation. *Biol Res* 2013; **46**: 441-451 [PMID: 24510146 DOI: 10.4067/S0716-97602013000400015]
- 57 **Hollander AP**, Dickinson SC, Kafienah W. Stem cells and cartilage development: complexities of a simple tissue. *Stem Cells* 2010; **28**: 1992-1996 [PMID: 20882533 DOI: 10.1002/stem.534]
- 58 **Huey DJ**, Hu JC, Athanasiou KA. Unlike bone, cartilage regeneration remains elusive. *Science* 2012; **338**: 917-921 [PMID: 23161992 DOI: 10.1126/science.1222454]
- 59 **Jakobsen RB**, Shahdadfar A, Reinholt FP, Brinckmann JE. Chondrogenesis in a hyaluronic acid scaffold: comparison between chondrocytes and MSC from bone marrow and adipose tissue. *Knee Surg Sports Traumatol Arthrosc* 2010; **18**: 1407-1416 [PMID: 20020100 DOI: 10.1007/s00167-009-1017-4]
- 60 **Orth P**, Rey-Rico A, Venkatesan JK, Madry H, Cucchiari M. Current perspectives in stem cell research for knee cartilage repair. *Stem Cells Cloning* 2014; **7**: 1-17 [PMID: 24520197 DOI: 10.2147/SCCAA.S42880]
- 61 **Johnstone B**, Alini M, Cucchiari M, Dodge GR, Eglin D, Guilak F, Madry H, Mata A, Mauck RL, Semino CE, Stoddart MJ. Tissue engineering for articular cartilage repair--the state of the art. *Eur Cell Mater* 2013; **25**: 248-267 [PMID: 23636950]
- 62 **Musumeci G**, Castrogiovanni P, Leonardi R, Trovato FM, Szychlinska MA, Di Giunta A, Loreto C, Castorina S. New perspectives for articular cartilage repair treatment through tissue engineering: A contemporary review. *World J Orthop* 2014; **5**: 80-88 [PMID: 24829869 DOI: 10.5312/wjo.v5.i2.80]
- 63 **Arabadjiev A**, Petkova R, Momchilova A, Chakarov S, Pankov R. Of mice and men – differential mechanisms of maintaining the undifferentiated state in mESC and hESC. *BioDiscovery* 2012; **3**: 1 [DOI: 10.7750/BioDiscovery.2012.3.1]
- 64 **Lefort N**, Feyeux M, Bas C, Féraud O, Bennaceur-Grisicelli A, Tachdjian G, Peschanski M, Perrier AL. Human embryonic stem cells reveal recurrent genomic instability at 20q11.21. *Nat Biotechnol* 2008; **26**: 1364-1366 [PMID: 19029913 DOI: 10.1038/nbt.1509]
- 65 **Spits C**, Mateizel I, Geens M, Mertzaniadou A, Staessen C, Vandekelde Y, Van der Elst J, Liebaers I, Sermon K. Recurrent chromosomal abnormalities in human embryonic stem cells. *Nat Biotechnol* 2008; **26**: 1361-1363 [PMID: 19029912]

- DOI: 10.1038/nbt.1510]
- 66 **Hyka-Nouspikel N**, Desmarais J, Gokhale PJ, Jones M, Meuth M, Andrews PW, Nouspikel T. Deficient DNA damage response and cell cycle checkpoints lead to accumulation of point mutations in human embryonic stem cells. *Stem Cells* 2012; **30**: 1901-1910 [PMID: 22821732 DOI: 10.1002/stem.1177]
- 67 **Petkova R**, Chelenkova P, Georgieva E, Chakarov St. What's your poison? Impact of individual repair capacity on the outcomes of genotoxic therapies in cancer. Part I - role of individual repair capacity in the constitution of risk for late-onset multifactorial disease. *Biotechnol Biotec Eq* 2013; **27**: 4208-4216 [DOI: 10.5504/BBEQ.2013.0097]
- 68 **Lund RJ**, Närvä E, Lahesmaa R. Genetic and epigenetic stability of human pluripotent stem cells. *Nat Rev Genet* 2012; **13**: 732-744 [PMID: 22965355 DOI: 10.1038/nrg3271]
- 69 **Rocha CR**, Lerner LK, Okamoto OK, Marchetto MC, Menck CF. The role of DNA repair in the pluripotency and differentiation of human stem cells. *Mutat Res* 2013; **752**: 25-35 [PMID: 23010441 DOI: 10.1016/j.mrrev.2012.09.001]
- 70 **Chelenkova P**, Petkova R, D' Ascanio I, Zhelev N, Chakarov S. In sickness and in health: a set of markers for individual repair capacity in risk assessment, monitoring and prognosis of human disease. *Curr Opin Biotech* 2013; **24**: 105 [DOI: 10.1016/j.copbio.2013.05.322]
- 71 **Petkova R**, Chelenkova P, Georgieva E, Chakarov St. What's your poison? Impact of individual repair capacity on the outcomes of genotoxic therapies in cancer. Part II - information content and validity of biomarkers for individual repair capacity in the assessment of outcomes of anticancer therapy. *Biotechnol Biotec Eq* 2014; **28**: 2-7 [DOI: 10.1080/13102818.2014.902532]
- 72 **Shetzer Y**, Kagan S, Koifman G, Sarig R, Kogan-Sakin I, Charni M, Kaufman T, Zapatka M, Molchadsky A, Rivlin N, Dinowitz N, Levin S, Landan G, Goldstein I, Goldfinger N, Pe'er D, Radlwimmer B, Lichter P, Rotter V, Aloni-Grinstein R. The onset of p53 loss of heterozygosity is differentially induced in various stem cell types and may involve the loss of either allele. *Cell Death Differ* 2014; **21**: 1419-1431 [PMID: 24832469 DOI: 10.1038/cdd.2014.57]
- 73 **Ragle RL**, Sawitzke AD. Nutraceuticals in the management of osteoarthritis : a critical review. *Drugs Aging* 2012; **29**: 717-731 [PMID: 23018608 DOI: 10.1007/s40266-012-0006-3]
- 74 **Akhtar N**, Haqqi TM. Current nutraceuticals in the management of osteoarthritis: a review. *Ther Adv Musculoskelet Dis* 2012; **4**: 181-207 [PMID: 22850529 DOI: 10.1177/1759720X11436238]

**P- Reviewer:** Chen YK, Fenichel I, Yao YC, Zhai G  
**S- Editor:** Tian YL **L- Editor:** A **E- Editor:** Lu YJ







Published by **Baishideng Publishing Group Inc**

8226 Regency Drive, Pleasanton, CA 94588, USA

Telephone: +1-925-223-8242

Fax: +1-925-223-8243

E-mail: [bpgoffice@wjgnet.com](mailto:bpgoffice@wjgnet.com)

Help Desk: <http://www.wjgnet.com/esps/helpdesk.aspx>

<http://www.wjgnet.com>

